World Sleep Industry ENCYCLOPEDIA

Doxepin

2.1.1

Ingredient identity, dosage-form tiers, and mechanism

Doxepin is a tricyclic antidepressant ingredient that is also available in a dedicated low-dose oral formulation for insomnia. At low exposure, its sleep-promoting effect is explained mainly by potent central histamine H1-receptor blockade. At higher antidepressant doses, serotonin and noradrenaline reuptake effects become more prominent, along with greater anticholinergic, sedating, and cardiovascular effects. The shared name “doxepin” does not make every strength the same kind of antihistamine sleep aid.

Low-dose insomnia tablets, capsules or oral solution used for depression, and topical cream used for itching differ in strength, approved purpose, absorption, and risk. They cannot be converted by tablet count, capsule count, liquid volume, or amount applied. Current United States low-dose labeling is for adult insomnia characterized by difficulty maintaining sleep, while antidepressant capsules are indicated for major depressive disorder in adults. Authorization of one product for insomnia does not permit self-dividing an antidepressant product for sleep, and a topical product must never be swallowed.

Sleep-maintenance role, magnitude of evidence, and causal assessment

The main benefits in low-dose doxepin trials were reductions in wake time after sleep onset, longer total sleep time, and better sleep efficiency, particularly during the later part of the night. Improvement in sleep-onset latency was small or inconsistent. Registration-supporting studies lasted up to about three months, and a systematic review described small-to-moderate average effects on sleep maintenance and duration; the low-dose studies were also industry sponsored. Improvement in an objective polysomnographic measure does not guarantee an equal improvement in each person’s perceived restoration, daytime function, or quality of life.

A professional guideline gives only a weak suggestion for adult sleep-maintenance insomnia, with low-quality evidence because of imprecision and possible publication bias. Doxepin may not address insomnia that is primarily delayed sleep onset, inadequate sleep opportunity, a required early schedule, or awakenings caused by sleep apnea, restless legs, pain, nocturia, hot flashes, mania, alcohol, or another medicine. Cognitive behavioral therapy for insomnia remains a first-line or parallel treatment for chronic insomnia. Failure to improve after seven to ten days, or new cognitive or behavioral abnormalities, calls for reassessment rather than automatic escalation.

Bedtime timing, food effects, and long half-life

Doxepin must be used according to the exact product and prescription. Current United States labeling for the low-dose insomnia tablet specifies use within 30 minutes of bedtime and at least three hours after a meal to reduce delayed onset and next-day effects; activities afterward should be limited to preparing for bed. An extra dose should not be taken after a nocturnal awakening, and a missed dose or uncertainty about a prior dose should not lead to doubling. An antidepressant capsule should not be split, opened, or estimated to create an improvised low dose. Anyone who still needs to drive, provide care, or cannot reserve a full sleep opportunity should clarify the plan with the prescriber.

After a low-dose tablet in the fasted state, median peak time is about 3.5 hours. A high-fat meal can increase total and peak exposure and delay the peak by about three additional hours. The apparent terminal half-life is about 15 hours for doxepin and about 31 hours for the active metabolite nordoxepin; variation in CYP2C19 and CYP2D6 metabolism can further change exposure. A low milligram number does not mean the drug has disappeared by morning, and feeling awake does not prove intact attention, balance, reaction time, or driving performance.

Nocturnal behavior, daytime function, and anticholinergic risk

Hypnotic use has been associated with driving, preparing or eating food, making calls, sexual activity, or sleepwalking while not fully awake, often with no later memory. Alcohol, other central depressants, and excessive doses increase this risk. Sleep-driving or another complex behavior requires stopping further self-administration and immediate contact with the prescriber. Hallucinations, abnormal thinking, worsening depression, and suicidal thoughts also require prompt assessment. Next-day somnolence, sedation, and nausea are common enough to matter; an average trial result showing little residual impairment is not an individual driving clearance.

Anticholinergic and orthostatic effects grow with dose and exposure and may present in older adults as dry mouth, constipation, blurred vision, urinary retention, confusion, falls, or syncope. Current low-dose insomnia labeling contraindicates use with untreated narrow-angle glaucoma or severe urinary retention. Higher doses do not retain the same risk profile as the dedicated low-dose product. Geriatric prescribing criteria classify doxepin above the low-dose insomnia range as a strongly anticholinergic medicine to avoid; this distinction does not mean that a lower dose is completely safe for every older person.

Interactions, psychiatric risks, and formulation changes

Combining doxepin with a monoamine oxidase inhibitor, or switching within the required washout period, can cause severe or fatal reactions; the exact interval must follow the specific medicines and current labels. Inhibitors of CYP2C19 or CYP2D6 can raise doxepin exposure. Cimetidine roughly doubles exposure to the low-dose product, and medicines such as sertraline can also raise exposure and worsen psychomotor performance. Alcohol, opioids, benzodiazepines, other hypnotics, and sedating antihistamines can add to sedation. Halving doxepin independently is not a safe way to cancel an interaction.

Higher-dose antidepressant treatment requires screening for bipolar disorder and surveillance for suicidal thoughts, mania, and serotonin syndrome during initiation and dose changes. With other serotonergic drugs, agitation, fever, sweating, heart-rate or blood-pressure changes, tremor, rigidity, diarrhea, and altered consciousness require urgent evaluation. Antidepressant regimens are generally tapered when stopped. The absence of a typical withdrawal or rebound signal in low-dose insomnia trials cannot automatically be applied to long-term higher-dose treatment. Any switch between capsules and insomnia tablets, in either direction, requires a new check of indication, total dose, and risk.

Special populations, respiratory risk, and overdose response

Older adults may be more susceptible to confusion and excessive sedation, while hepatic impairment and CYP2C19 or CYP2D6 poor metabolism may increase exposure. The low-dose product has not been adequately studied in obstructive sleep apnea; compromised respiratory function warrants caution, and current labeling ordinarily does not recommend it in severe sleep apnea. Pediatric safety and effectiveness are not established. Late-pregnancy exposure to tricyclics may cause poor neonatal adaptation. Doxepin and nordoxepin enter human milk, and reports include excessive infant sedation, respiratory depression, and feeding difficulty; current labeling does not recommend breastfeeding during treatment.

Doxepin overdose can rapidly become critical tricyclic poisoning, with dysrhythmia, QRS widening, severe hypotension, seizures, respiratory or central nervous system depression, and coma; deterioration may be delayed. An accidental or duplicate dose, ingestion by a child, or intentional overdose requires immediate emergency and poison-center contact, with the package, possible amount, timing, and co-ingestants reported. Waiting for the person to wake or inducing vomiting at home is unsafe. The facts that doxepin is not controlled and that low-dose trials did not show typical physical dependence do not make sharing, stockpiling, or a full bottle harmless.

Follow-up, storage, and encyclopedia boundaries

Follow-up should document the exact formulation and strength, timing relative to food and bedtime, bed and wake times, number and duration of awakenings, morning alertness, near-falls, complex sleep behavior, mood, and self-harm thoughts, while reviewing alcohol, nonprescription antihistamines, and other sedatives. If awakenings do not improve meaningfully, daytime function worsens, the true problem is sleep onset or respiratory events, or urinary retention, eye pain with visual change, mania, or serotonin-syndrome features appear, the diagnosis and plan require review rather than self-escalation.

Oral products should remain in the labeled original package or a compliant identifiable dispensing container, protected from light and stored at the temperature specified on the label, inaccessible to children, visitors, and anyone at self-harm risk. Topical doxepin should be stored separately from oral products. Strengths, indications, and warnings differ across jurisdictions, so the current information for the actual product is controlling. This entry explains low-dose sleep-maintenance evidence and multi-formulation safety boundaries; it does not provide a personal dose, promise faster sleep onset or more deep sleep, or replace CBT-I, sleep-apnea assessment, depression follow-up, or emergency care.